Standard Nivolumab Dosing for Adults
Nivolumab (Opdivo), a PD-1 inhibitor used for cancers like melanoma, lung cancer, and renal cell carcinoma, has dosing that varies by indication, body weight, and combination therapy. The typical flat dose for adults across most monotherapy indications is 240 mg intravenously every 2 weeks or 480 mg every 4 weeks, administered over 30 minutes.[1][2]
For weight-based dosing in certain cases (e.g., some pediatric extensions or specific adult protocols), it's 3 mg/kg every 2 weeks or 360 mg/m² every 3 weeks.[1]
How Dosing Differs by Cancer Type
- Melanoma (monotherapy): 240 mg every 2 weeks or 480 mg every 4 weeks.
- Non-small cell lung cancer (NSCLC, monotherapy): Same as above.
- Renal cell carcinoma (with ipilimumab): Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for 4 doses, then nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks.
- Hodgkin lymphoma: 240 mg every 2 weeks or 3 mg/kg every 2 weeks.
- Hepatocellular carcinoma: 240 mg every 2 weeks or 480 mg every 4 weeks.[2][3]
Doses are capped or adjusted for low body weight in combinations; always confirm with prescribing info for the exact regimen.
Dose Adjustments for Side Effects or Special Cases
Reduce to 240 mg every 4 weeks or hold for immune-related adverse events like severe pneumonitis or colitis. Permanently discontinue if grade 4 toxicity occurs or grade 3 recurs.[2]
No routine adjustments for mild liver/kidney impairment, but monitor closely. Elderly patients follow standard adult dosing without changes.[1][3]
How Nivolumab Is Administered
Given as a 30-minute IV infusion through a sterile, low-protein-binding filter. Premedicate with acetaminophen and antihistamine for first infusions if hypersensitivity risk is high. Compatible with 0.9% sodium chloride or 5% dextrose.[2]
Why Doses Shifted from Weight-Based to Flat
Early regimens used 3 mg/kg every 2 weeks for efficacy consistency. Flat dosing (240/480 mg) was approved in 2017-2018 after trials showed equivalent exposure and outcomes, simplifying administration.[1][4]
Common Patient Questions on Dosing
Patients often ask about infusion time (30 min), frequency fatigue, or home administration—no home option exists; it's outpatient only. Cost per dose averages $13,000-$30,000 uninsured, covered by most insurance for approved uses.[3]
[1]: Opdivo Prescribing Information (Bristol Myers Squibb, 2023)
[2]: FDA Label for Nivolumab
[3]: Drugs.com - Nivolumab Dosage Guide
[4]: DrugPatentWatch.com - Nivolumab Patents and Exclusivity